These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 29290248)

  • 1. Stereotactic body radiation therapy for isolated hilar and mediastinal non-small cell lung cancers.
    Horne ZD; Richman AH; Dohopolski MJ; Clump DA; Burton SA; Heron DE
    Lung Cancer; 2018 Jan; 115():1-4. PubMed ID: 29290248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose hilar and mediastinal stereotactic body radiation therapy for non-small cell lung cancer: Analysis of outcomes in patients receiving one or multiple courses of treatment.
    Kowalchuk RO; Waters MR; Richardson M; Spencer K; Larner JM; Kersh CR
    Thorac Cancer; 2020 Jul; 11(7):2005-2013. PubMed ID: 32469465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated Nodal Failure after Stereotactic Body Radiotherapy for Lung Cancer: The Role for Salvage Mediastinal Radiotherapy.
    Ward MC; Oh SC; Pham YD; Woody NM; Marwaha G; Videtic GM; Stephans KL
    J Thorac Oncol; 2016 Sep; 11(9):1558-64. PubMed ID: 27223455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of invasive mediastinal nodal staging versus positron emission tomography staging alone for early-stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Schonewolf CA; Verma V; Post CM; Berman AT; Frick MA; Vachani A; Lin C; Simone CB
    Lung Cancer; 2018 Mar; 117():53-59. PubMed ID: 28800837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of incidental mediastinal and hilar irradiation delivered during definitive stereotactic body radiation therapy for peripheral non-small cell lung cancer.
    Martin KL; Gomez J; Nazareth DP; Warren GW; Singh AK
    Med Dosim; 2012; 37(2):182-5. PubMed ID: 21978531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review.
    Cozzi S; Alì E; Bardoscia L; Najafi M; Botti A; Blandino G; Giaccherini L; Ruggieri MP; Augugliaro M; Iori F; Sardaro A; Iotti C; Ciammella P
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.
    Rwigema JC; Chen AM; Wang PC; Lee JM; Garon E; Lee P
    Clin Lung Cancer; 2014 Jul; 15(4):287-93. PubMed ID: 24594401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Definitive radiotherapy for hilar and/or mediastinal lymph node metastases after stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer: 5-year results.
    Manabe Y; Shibamoto Y; Baba F; Yanagi T; Iwata H; Miyakawa A; Murai T; Okuda K
    Jpn J Radiol; 2018 Dec; 36(12):719-725. PubMed ID: 30218253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer in the very elderly (≥80years old): Extremely safe and effective.
    Kreinbrink P; Blumenfeld P; Tolekidis G; Sen N; Sher D; Marwaha G
    J Geriatr Oncol; 2017 Sep; 8(5):351-355. PubMed ID: 28739159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT; Mitra N; Xanthopoulos E; Evans T; Stevenson J; Langer C; Kucharczuk JC; Lin L; Rengan R
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):340-7. PubMed ID: 22104359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC).
    von Reibnitz D; Shaikh F; Wu AJ; Treharne GC; Dick-Godfrey R; Foster A; Woo KM; Shi W; Zhang Z; Din SU; Gelblum DY; Yorke ED; Rosenzweig KE; Rimner A
    Acta Oncol; 2018 Nov; 57(11):1567-1573. PubMed ID: 29873277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly patients undergoing SBRT for inoperable early-stage NSCLC achieve similar outcomes to younger patients.
    Mancini BR; Park HS; Harder EM; Rutter CE; Corso CD; Decker RH; Husain ZA
    Lung Cancer; 2016 Jul; 97():22-7. PubMed ID: 27237023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.
    Woody NM; Stephans KL; Marwaha G; Djemil T; Videtic GM
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):325-31. PubMed ID: 25841625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.
    Marwaha G; Stephans KL; Woody NM; Reddy CA; Videtic GM
    J Thorac Oncol; 2014 Nov; 9(11):1693-7. PubMed ID: 25185531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Shahi J; Poon I; Ung YC; Tsao M; Bjarnason GA; Malik NH; Zhang L; Louie AV; Cheung P
    Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):764-774. PubMed ID: 33115687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
    Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
    Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
    Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
    Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study.
    Miyakawa A; Shibamoto Y; Baba F; Manabe Y; Murai T; Sugie C; Yanagi T; Takaoka T
    Radiat Oncol; 2017 Sep; 12(1):152. PubMed ID: 28893300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study.
    Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
    Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Enlarged Nonhypermetabolic Lymph Nodes on Outcomes After Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer.
    Verma V; Schonewolf CA; Cushman TR; Post CM; Doms A; Berman AT; DeVries M; Katz SI; Simone CB
    Clin Lung Cancer; 2018 Nov; 19(6):502-510. PubMed ID: 30111509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.